Ramat-Gan, Israel: The administration of liquid cannabis extracts containing THC has been associated with the mitigation of various symptoms of Alzheimer’s-related agitation and dementia, according to observational trial data published online ahead of print in The Journal of Alzheimer’s Disease.
Israeli investigators assessed the use of cannabis oil as an adjunct pharmacotherapy treatment in ten Alzheimer’s disease patients over a period of several weeks. Researchers reported that drug administration was associated with a significant reduction in patients’ symptom severity scores. Specifically, cannabis oil ingestion corresponded with decreased levels of aggression, irritability, apathy, and delusions.
Investigators concluded, “Adding medical cannabis oil to Alzheimer’s disease patients pharmacotherapy is safe and a promising treatment option.”
The administration of dronabinol (oral synthetic THC in pill form) has previously been reported to reduce Alzheimer’s-induced agitation, while preclinical studies have theorized that cannabinoids may be neuroprotective against the onset of the disease.
For more information, please contact Paul Armentano, NORML Deputy Director, at: firstname.lastname@example.org. Full text of the study, “Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: An open label, add-on, pilot study,” appears in The Journal of Alzheimer’s Disease.